SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of October 19, 2026, SYRE stock price climbed to $84.00 with 370,175 million shares trading.

SYRE has a beta of 1.68, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.11 to the broad based SPY ETF.

SYRE has a market cap of $7.85 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, VB, IWM, XBI, VBR.

SYRE has outperformed the market in the last year with a return of +277.7%, while the SPY ETF gained +17.5%. However, in the most recent history, SYRE shares have underperformed the stock market with its stock returning -10.8% in the last 3 month period and -9.9% for the last 2 week period, while SPY has returned +2.6% and -0.2%, respectively.

SYRE support price is $76.67 and resistance is $83.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.